Furthermore, more work is needed to investigate the mechanisms of tau interaction with other biomarkers of AD neuropathologic change, both specific and non-specific, and non-AD copathologies in disease development/acceleration so that we can better identify what combination of factors need to be treated [69]. This evidence concerns the gene MAPT and Alzheimer disease.